MYRIAD GENETICS, INC.

MYGN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Revenue $771.4M $753.8M $723.1M $778.2M $613.2M $496.0M $402.1M $362.6M
Cost of Revenue $145.2M $132.8M $132.8M $96.1M $64.4M $51.5M $45.6M $44.3M
Gross Profit $626.2M $621.0M $590.3M $682.1M $548.8M $444.6M $356.4M $318.4M
Gross Margin 81.2% 82.4% 81.6% 87.7% 89.5% 89.6% 88.6% 87.8%
Operating Expenses
Research & Development $74.4M $70.6M $75.5M $67.5M $53.7M $42.6M $27.8M $21.9M
SG&A Expense $439.9M $359.2M $366.0M $327.1M $251.8M $208.4M $169.8M $161.4M
Operating Income $44.0M $153.4M $133.6M $274.4M $228.0M $180.3M $157.8M $135.1M
Operating Margin 5.7% 20.4% 18.5% 35.3% 37.2% 36.4% 39.2% 37.2%
Interest Expense $6.0M $300.0K $200.0K
Pretax Income $36.2M $156.0M $134.3M $277.8M $233.3M $184.5M $159.7M $140.8M
Income Tax Expense $19.0M $38.8M $54.5M $101.6M $86.1M $72.4M $58.9M $-11.5M
Net Income $17.4M $117.2M $79.8M $176.2M $147.2M $112.2M $100.7M $152.3M
Net Margin 2.3% 15.5% 11.0% 22.6% 24.0% 22.6% 25.0% 42.0%
EPS (Basic) $0.25 $1.67 $1.12 $2.33 $1.82 $1.33 $1.12 $1.58
EPS (Diluted) $0.25 $1.60 $1.07 $2.25 $1.77 $1.30 $1.10 $1.54
Shares Outstanding (Basic) 68.3M 70.0M 71.3M 75.7M 80.9M 84.6M 89.8M 96.3M
Shares Outstanding (Diluted) 68.8M 73.4M 74.5M 78.2M 83.3M 86.5M 91.7M 99.2M
Dividends Per Share
← Newer Page 2 of 3 Older →